E-resources
-
Steigbigel, Roy T; Cooper, David A; Kumar, Princy N; Eron, Joseph E; Schechter, Mauro; Markowitz, Martin; Loutfy, Mona R; Lennox, Jeffrey L; Gatell, Jose M; Rockstroh, Jurgen K; Katlama, Christine; Yeni, Patrick; Lazzarin, Adriano; Clotet, Bonaventura; Zhao, Jing; Chen, Joshua; Ryan, Desmond M; Rhodes, Rand R; Killar, John A; Gilde, Lucinda R; Strohmaier, Kim M; Meibohm, Anne R; Miller, Michael D; Hazuda, Daria J; Nessly, Michael L; DiNubile, Mark J; Isaacs, Robin D; Nguyen, Bach-Yen; Teppler, Hedy
The New England journal of medicine, 07/2008, Volume: 359, Issue: 4Journal Article, Web Resource
For patients infected with multidrug-resistant human immunodeficiency virus type 1 (HIV-1), therapeutic options are limited. Raltegravir is a new molecule that inhibits HIV integrase. In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). In two phase 3 studies, raltegravir was found to be superior to placebo, in the context of optimized background antiviral therapy, in suppressing HIV viral load at 48 weeks (62.1% vs. 32.9%). Highly active antiretroviral therapy is the standard of care for patients with advanced human immunodeficiency virus (HIV) infection. 1 Combination regimens have resulted in improved survival, decreased morbidity, and cost-effective care for patients with a CD4 count of less than 350 per cubic millimeter. 2 – 8 However, viral suppression cannot always be achieved or sustained with standard treatments because of the development of viral resistance, toxic effects of drugs, or lack of adherence. 9 – 18 The majority of HIV-infected patients in whom highly active antiretroviral therapy fails have resistant viral quasispecies. 12 – 15 , 19 , 20 Cross-resistance to agents within a drug class may exhaust . . .
Author
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Shelf entry
Permalink
- URL:
Impact factor
Access to the JCR database is permitted only to users from Slovenia. Your current IP address is not on the list of IP addresses with access permission, and authentication with the relevant AAI accout is required.
Year | Impact factor | Edition | Category | Classification | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Select the library membership card:
If the library membership card is not in the list,
add a new one.
DRS, in which the journal is indexed
Database name | Field | Year |
---|
Links to authors' personal bibliographies | Links to information on researchers in the SICRIS system |
---|
Source: Personal bibliographies
and: SICRIS
The material is available in full text. If you wish to order the material anyway, click the Continue button.